Previous 10 | Next 10 |
2023-05-25 18:21:14 ET If you’re like many retail traders in the stock market today, penny stocks are a popular prospect. This article looks at some of the most active penny stocks today with late-breaking momentum. They could also be on the radar of traders before next week. But...
2023-05-24 12:15:06 ET BioLineRx Ltd. (BLRX) Q1 2023 Earnings Conference Call May 24, 2023, 10:00 AM ET Company Participants John Lacey - Investor Relations Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Holly May - Chief Commerc...
2023-05-24 07:06:19 ET Biolinerx press release ( NASDAQ: BLRX ): Q1 GAAP EPS of -$0.01 beats by $0.13 . As of March 31, 2023, the company held cash, cash equivalents, and short-term bank deposits of $43.3M and anticipates this will be sufficient to fund operations...
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates PR Newswire On Track for September PDUFA Target Action Date on NDA for Motixafortide in Stem Cell Mobilization (SCM) for Autologous Transplantation in Multiple Myeloma (MM) ...
2023-05-23 12:52:36 ET biolinerx ( NASDAQ: BLRX ) is scheduled to announce Q1 earnings results on Wednesday, May 24th, before market open. The consensus EPS Estimate is -$0.14 Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. ...
BioLineRx to Report First Quarter 2023 Results on May 24, 2023 PR Newswire Management to Hold Conference Call at 10:00 a.m. EDT TEL AVIV, Israel , May 17, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharm...
2023-05-04 13:56:05 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Most of the biggest biotech stocks on the market started off as unknown penny stocks . Look at Axsome Therapeutics (NASDAQ: AXSM ), for example. At one time, it was a $2.50 ...
2023-04-25 07:36:00 ET Pre-commercial-stage biopharmaceutical company focused on oncology, BioLineRx ( NASDAQ: BLRX ) received formal notice from Nasdaq that the company has regained compliance with the minimum bid price requirement. The company was notified on Novemb...
BioLineRx Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire TEL AVIV, Israel , April 25, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it ...
BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma PR Newswire - GENESIS trial achieved statistical significance (p<0.0...
News, Short Squeeze, Breakout and More Instantly...
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) PR Newswire - Investigator-initiated study in...
Orkla ASA ADR (ORKLY) is expected to report for Q1 2024 Cosmos Health Inc. (COSM) is expected to report $-0.14 for Q1 2024 Basilea Pharmaceutica AG Registered Shares (BPMUF) is expected to report for Q1 2024 DCC Plc (DCCPF) is expected to report for Q4 2024 Datatec Ltd ADR (DTTLY)...
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting PR Newswire New analysis of biopsy samples demonstrate...